ERBB2 (Ab-1248) Antibody

What is the ERBB2 (Ab-1248) Antibody and what specific epitope does it target?

The ERBB2 (Ab-1248) Antibody is a polyclonal antibody specifically designed to detect endogenous levels of ERBB2 (HER2) protein when phosphorylated at tyrosine 1248 (pY1248). This antibody targets the phosphorylated peptide sequence surrounding amino acids 1246-1250 (P-E-Y-L-G) of human ERBB2 . Tyrosine 1248 represents one of the major autophosphorylation sites of ERBB2 and serves as a critical indicator of the receptor's activation status . This specificity makes the antibody particularly valuable for assessing ERBB2 signaling pathway activation in various experimental contexts.

What are the validated applications for ERBB2 (Ab-1248) Antibody?

The ERBB2 (Ab-1248) Antibody has been validated for multiple laboratory applications:

Multiple manufacturers have validated these applications through experimental testing on human cancer cell lines, including MDA-MB-468 breast cancer cells and A431 epithelial carcinoma cells, as well as various human tissue samples .

What is the optimal storage condition for ERBB2 (Ab-1248) Antibody?

For long-term preservation, ERBB2 (Ab-1248) Antibody should be stored at -20°C in its original formulation, which typically consists of phosphate buffered saline (without Mg²⁺ and Ca²⁺), pH 7.4, 150mM NaCl, 0.02% sodium azide, and 50% glycerol . For short-term use (within a few weeks), the antibody can be stored at 4°C. Repeated freeze-thaw cycles should be avoided as they may compromise antibody performance. The typical shelf life when properly stored is approximately 12 months from the date of receipt .

What are the critical controls needed when using ERBB2 (Ab-1248) Antibody?

Proper experimental design with ERBB2 (Ab-1248) Antibody requires several controls:

• Positive Control: Cell lines known to express high levels of phosphorylated ERBB2, such as EGF-stimulated A431 cells or pervanadate-treated MDA-MB-468 cells .

• Negative Control:

  • Untreated versions of positive control cells

  • Samples treated with phosphatase to remove phosphorylation

  • Normal human serum in place of primary antibody for IHC

• Specificity Control: Use of competing phosphorylated and non-phosphorylated peptides to confirm antibody specificity.

• Loading Control: Detection of a housekeeping protein (e.g., β-actin) to ensure equal protein loading.

• Isotype Control: For flow cytometry or IHC applications, use of a non-specific antibody of the same isotype.

These controls help validate that observed signals are specifically due to phosphorylated ERBB2 at Y1248 rather than non-specific binding or experimental artifacts.

How should samples be prepared to preserve phosphorylation status for ERBB2 (Ab-1248) Antibody detection?

Preservation of phosphorylation status is critical for accurate detection with ERBB2 (Ab-1248) Antibody:

• Cell/Tissue Lysis: Use lysis buffers containing phosphatase inhibitors (e.g., sodium orthovanadate, sodium fluoride, β-glycerophosphate) to prevent dephosphorylation during sample processing.

• Sample Handling: Process samples quickly and maintain cold temperatures (4°C or below) throughout preparation.

• Fixation for IHC/IF: For tissue sections, use fixation methods that preserve phospho-epitopes. Heat-induced epitope retrieval using basic antigen retrieval reagents has been shown to be effective for ERBB2 pY1248 detection .

• Protein Denaturation: For Western blotting, denature proteins at 100°C for 5 minutes in SDS-PAGE loading buffer containing reducing agents .

• Storage of Prepared Samples: Store prepared lysates at -80°C with phosphatase inhibitors, and avoid multiple freeze-thaw cycles.

These precautions ensure that the phosphorylation status of ERBB2 remains intact during experimental procedures, providing more reliable and reproducible results.

What is the significance of ERBB2 phosphorylation at Y1248 in cancer research?

ERBB2 phosphorylation at Y1248 has profound significance in cancer research:

• Activation Marker: Phosphorylation at Y1248 is one of the major autophosphorylation sites that reflects the activation status of the ERBB2 receptor .

• Signaling Pathway Activation: This phosphorylation event couples ERBB2 to the Ras-Raf-MAP kinase signal transduction pathway, driving cellular proliferation and survival .

• Prognostic Value: Studies have demonstrated that pY1248-ERBB2 is associated with poor clinical outcomes in breast cancer patients, independent of total ERBB2 expression levels .

• Therapeutic Response Prediction: The phosphorylation status at Y1248 may predict response to ERBB2-targeted therapies such as tyrosine kinase inhibitors .

• Correlation with Other Biomarkers: Phosphorylated ERBB2 correlates positively with EGFR and total ERBB2 expression, and inversely with hormone receptors (ER, PgR) and ERBB4 expression .

This phosphorylation site serves as a critical biomarker for understanding ERBB2-driven oncogenesis and may guide personalized treatment strategies in cancer patients.

How can ERBB2 (Ab-1248) Antibody be used to study resistance mechanisms to HER2-targeted therapies?

ERBB2 (Ab-1248) Antibody provides valuable insights into resistance mechanisms to HER2-targeted therapies:

• Bypass Pathway Activation: The antibody can help identify persistent ERBB2 phosphorylation despite treatment, indicating bypass activation through alternative pathways.

• Mutation Detection: Different ERBB2 mutation hotspots across tumor types can affect the binding pocket volume and drug sensitivity . Monitoring pY1248 levels can help assess if mutations alter signaling without affecting antibody recognition.

• Combination Therapy Assessment: When evaluating combination treatments, such as poziotinib with T-DM1, the antibody can monitor changes in ERBB2 phosphorylation status and surface expression levels .

• Longitudinal Studies: Sequential biopsies or liquid biopsy-derived samples can be assessed for changes in pY1248-ERBB2 levels during treatment and at progression to understand resistance evolution.

• Cell Line Models: In resistant cell lines, comparing pY1248-ERBB2 levels with parental sensitive lines can reveal alterations in activation patterns.

By providing a direct measurement of ERBB2 activation status, this antibody serves as a critical tool for understanding and potentially overcoming therapeutic resistance.

What are the emerging applications of ERBB2 (Ab-1248) Antibody in neurodegenerative disease research?

Recent research has revealed surprising applications of ERBB2 (Ab-1248) Antibody in neurodegenerative disease studies:

• Parkinson's Disease Biomarker: A recent study identified ErbB2 pY-1248 as a promising biomarker for Parkinson's disease (PD) using reverse phase protein array (RPPA) technology and in vivo verification .

• Therapeutic Target Validation: Lapatinib, an ErbB2 tyrosine kinase inhibitor, was shown to attenuate dopaminergic neuron loss and PD-like behavior in zebrafish PD models, suggesting ErbB2 as a potential therapeutic target .

• Disease Mechanism Exploration: Increased expression of ErbB2 pY-1248 in MPTP-induced mouse PD models suggests a role for ERBB2 signaling in PD pathogenesis .

• Early Detection: As a potential early biomarker, ErbB2 pY-1248 may enable earlier intervention in PD, potentially improving treatment outcomes and reducing disease morbidity .

• Translational Applications: The antibody can be used to monitor ErbB2 activation in patient-derived samples, potentially aiding in patient stratification for clinical trials of ERBB2-targeting drugs in neurodegenerative diseases.

This emerging application highlights the expanding utility of ERBB2 (Ab-1248) Antibody beyond cancer research into other major disease areas.

What are the common issues encountered with ERBB2 (Ab-1248) Antibody and how can they be addressed?

Researchers commonly encounter several challenges when working with ERBB2 (Ab-1248) Antibody:

• Low Signal Intensity:

  • Ensure phosphorylation is preserved with fresh phosphatase inhibitors

  • Optimize antibody concentration (may need higher than recommended)

  • Extend primary antibody incubation time (overnight at 4°C)

  • Use signal amplification systems for IHC/IF applications

• High Background:

  • Increase blocking time and concentration (5% BSA or 5% milk)

  • Optimize washing steps (more frequent changes, longer durations)

  • Reduce secondary antibody concentration

  • Use more specific secondary antibodies

• Cross-Reactivity:

  • Perform peptide competition assays with phosphorylated and non-phosphorylated peptides

  • Use knockout/knockdown controls to confirm specificity

  • Optimize antibody dilution to minimize non-specific binding

• Variable Results Between Experiments:

  • Standardize sample collection and processing protocols

  • Use consistent positive controls across experiments

  • Maintain consistent antibody lots when possible

  • Quantify results relative to loading controls

• Tissue Penetration Issues in IHC:

  • Optimize antigen retrieval methods (test different pH buffers)

  • Consider tissue thickness and fixation time

  • Try alternative detection systems with higher sensitivity

Addressing these challenges requires systematic optimization of protocols specific to each experimental system and application.

How should quantitative analysis of ERBB2 phosphorylation be performed using ERBB2 (Ab-1248) Antibody?

Accurate quantification of ERBB2 phosphorylation using the ERBB2 (Ab-1248) Antibody requires careful methodological considerations:

These methodological approaches ensure reliable and reproducible quantification of ERBB2 phosphorylation status across different experimental platforms.

How does ERBB2 (Ab-1248) Antibody compare with other phospho-specific antibodies targeting different ERBB2 sites?

ERBB2 contains multiple phosphorylation sites with distinct functional implications. Here's how antibodies targeting pY1248 compare to those targeting other sites:

What criteria should researchers consider when selecting between different commercial ERBB2 (Ab-1248) antibodies?

When selecting an ERBB2 (Ab-1248) antibody for research applications, consider the following critical criteria:

• Antibody Characteristics:

  • Clonality: Polyclonal antibodies offer broader epitope recognition, while monoclonal or recombinant antibodies provide higher consistency between lots

  • Host Species: Consider compatibility with other antibodies in multiplex applications

  • Purification Method: Affinity-purified antibodies using phospho-specific peptides generally offer higher specificity

• Validation Data:

  • Application-Specific Validation: Ensure the antibody is validated for your specific application (WB, IHC, IF)

  • Species Cross-Reactivity: Verify reactivity with your species of interest

  • Cell/Tissue Types: Check if validation includes relevant models to your research

• Technical Specifications:

  • Sensitivity: Ability to detect endogenous levels of phosphorylated protein

  • Specificity: Evidence of phospho-specificity, such as phosphatase treatment controls

  • Recommended Dilutions: Starting points for optimization in your system

• Quality Control:

  • Lot-to-Lot Consistency: Evidence of consistent performance across production lots

  • Clear Citations: Published research demonstrating successful use in similar applications

• Formulation and Storage:

  • Concentration: Typically 1 mg/mL is standard

  • Buffer Composition: Compatible with intended applications

  • Available Formats: Consider conjugated versions for specific applications

Thorough evaluation of these criteria will help researchers select the most appropriate ERBB2 (Ab-1248) antibody for their specific research needs, potentially saving time and resources in optimization.

How might ERBB2 (Ab-1248) Antibody contribute to emerging liquid biopsy applications?

The potential for ERBB2 (Ab-1248) Antibody in liquid biopsy applications represents an exciting frontier:

• Circulating Tumor Cell (CTC) Analysis:

  • Detection of pY1248-ERBB2 in CTCs may provide real-time assessment of ERBB2 activation status without invasive biopsies

  • Monitoring treatment response through sequential blood draws

  • Potential for early detection of resistance mechanisms through changes in phosphorylation patterns

• Extracellular Vesicle (EV) Analysis:

  • EVs released by tumor cells may contain phosphorylated ERBB2 that can be detected using the antibody

  • Correlation between EV pY1248-ERBB2 content and tumor status could provide valuable clinical information

  • Development of microfluidic or nanoparticle-based enrichment strategies for enhanced detection

• Technical Adaptations:

  • Modified immunoprecipitation protocols to concentrate rare targets from blood samples

  • Integration with highly sensitive detection methods (digital ELISA, mass spectrometry)

  • Development of multiplexed assays to simultaneously assess multiple phospho-proteins

• Clinical Applications:

  • Monitoring minimal residual disease after treatment

  • Early detection of recurrence based on reactivation of ERBB2 signaling

  • Patient stratification for clinical trials of novel ERBB2-targeted therapies

The transition of ERBB2 (Ab-1248) Antibody applications from traditional tissue analysis to liquid biopsy platforms could significantly enhance non-invasive cancer monitoring and personalized treatment selection.

What are the potential applications of ERBB2 (Ab-1248) Antibody in studying the intersection of neurodegeneration and cancer biology?

The unexpected link between ERBB2 signaling in both cancer and neurodegenerative diseases opens fascinating research opportunities:

• Common Molecular Mechanisms:

  • Investigation of shared signaling pathways downstream of pY1248-ERBB2 in neural and cancer cells

  • Study of cellular stress responses influenced by ERBB2 activation in both disease contexts

  • Examination of mitochondrial dysfunction as a common feature in both conditions

• Therapeutic Crossover Potential:

  • Repurposing ERBB2-targeted cancer drugs like lapatinib for neurodegenerative diseases

  • Development of brain-penetrant ERBB2 inhibitors with dual applications

  • Investigation of differential effects of ERBB2 modulation in neural versus peripheral tissues

• Methodological Innovations:

  • Development of in vitro models expressing fluorescent reporters for live monitoring of ERBB2 phosphorylation

  • Creation of transgenic animal models with conditional ERBB2 activation in specific neural populations

  • Application of spatial transcriptomics and proteomics to correlate pY1248-ERBB2 with local gene expression patterns

• Clinical Correlations:

  • Epidemiological studies examining potential correlations between ERBB2-positive cancer history and neurodegenerative disease risk

  • Assessment of neurological side effects in cancer patients receiving ERBB2-targeted therapies

  • Evaluation of pY1248-ERBB2 in cerebrospinal fluid as a potential biomarker for early neurodegeneration

This emerging research area represents a significant paradigm shift in understanding the role of ERBB2 signaling beyond traditional cancer biology contexts.

What are the key considerations for optimizing Western blot protocols for ERBB2 (Ab-1248) Antibody?

Optimizing Western blot protocols for ERBB2 (Ab-1248) Antibody requires attention to several critical factors:

• Sample Preparation:

  • Lysis Buffer Selection: Use RIPA or other compatible buffers containing phosphatase inhibitors (sodium orthovanadate, sodium fluoride)

  • Protein Concentration: Load 20-40 μg of total protein per lane for cell lysates

  • Denaturation: Heat samples at 100°C for 5 minutes in SDS-PAGE loading buffer

• Gel Electrophoresis:

  • Gel Percentage: Use 8% or lower acrylamide gels for better resolution of high molecular weight ERBB2 (185 kDa)

  • Running Conditions: Lower voltage (80-100V) for better resolution

  • Protein Ladder: Include visible and pre-stained markers covering 100-250 kDa range

• Transfer Parameters:

  • Transfer Method: Wet transfer typically provides better results for large proteins

  • Transfer Time: Extended transfer (overnight at low voltage) may improve efficiency

  • Membrane Selection: PVDF membranes are recommended for phospho-protein detection

• Antibody Incubation:

  • Blocking: 5% BSA in TBST is preferred over milk for phospho-epitopes

  • Primary Antibody: 1:1000 dilution is standard, but may require optimization

  • Incubation Time: Overnight at 4°C for optimal sensitivity

  • Secondary Antibody: HRP-conjugated anti-rabbit IgG at 1:5000 dilution

• Detection and Visualization:

  • ECL System: Enhanced chemiluminescence substrates provide good sensitivity

  • Exposure Time: Start with short exposures (30 seconds) and increase as needed

  • Stripping and Reprobing: Gentle stripping conditions to preserve phospho-epitopes if reprobing is necessary

Following these optimization strategies will help ensure reliable and reproducible detection of phosphorylated ERBB2 at tyrosine 1248.

How can ERBB2 (Ab-1248) Antibody be effectively used in multiplexed immunofluorescence assays?

Multiplexed immunofluorescence with ERBB2 (Ab-1248) Antibody requires careful planning and optimization:

These approaches enable researchers to place ERBB2 phosphorylation in a broader biological context by simultaneously visualizing multiple cellular parameters.

What are the recommended validation experiments for researchers new to working with ERBB2 (Ab-1248) Antibody?

Researchers new to working with ERBB2 (Ab-1248) Antibody should perform the following validation experiments:

• Positive Control Verification:

  • Test the antibody on cell lines known to express phosphorylated ERBB2 (e.g., A431 cells treated with EGF, SKBR3 cells)

  • Compare treatment conditions known to induce phosphorylation (e.g., EGF stimulation, pervanadate treatment)

• Phospho-Specificity Confirmation:

  • Treat duplicate samples with lambda phosphatase prior to immunoblotting

  • Perform peptide competition assays using phosphorylated and non-phosphorylated peptides

  • Compare signals between phosphorylated and non-phosphorylated proteins

• Signal Validation in Multiple Techniques:

  • Cross-validate findings between Western blot and immunofluorescence/immunohistochemistry

  • Confirm subcellular localization is consistent with expected biology (e.g., membrane localization)

  • Verify molecular weight (approximately 185 kDa for ERBB2)

• Specificity Among Related Proteins:

  • Test antibody reactivity against related proteins (other ERBB family members)

  • Examine cross-reactivity with other phosphorylated tyrosine residues

• Functional Correlation:

  • Correlate phospho-ERBB2 detection with downstream pathway activation (e.g., MAPK phosphorylation)

  • Assess changes in phospho-signal following treatment with ERBB2 inhibitors like lapatinib

These validation experiments will establish the reliability and specificity of the antibody in the researcher's specific experimental system before proceeding to more complex studies.

What are the most significant recent publications that have utilized ERBB2 (Ab-1248) Antibody for breakthrough findings?

Recent significant publications utilizing ERBB2 (Ab-1248) Antibody have advanced our understanding in several research areas:

• Neurodegenerative Disease Biomarkers:

  • Jin et al. (2023) identified ErbB2 pY-1248 as a predictive biomarker for Parkinson's disease using reverse phase protein array technology and in vivo verification, demonstrating that lapatinib attenuated dopaminergic neuron loss and PD-like behavior in animal models .

• Cancer Mutation Analysis:

  • Robichaux et al. (2019) characterized the landscape and drug sensitivity of ERBB2 mutations across cancer types, finding that mutation hotspots vary across tumor types and affect drug sensitivity. They demonstrated that poziotinib enhances T-DM1 efficacy by increasing cell surface HER2 levels .

• Auditory System Regeneration:

  • Research using constitutively active ERBB2 receptors showed that signaling from ERBB2 can drive the activation of secondary pathways to regulate regeneration by endogenous stem-like cells in the cochlea, suggesting new models for hearing restoration .

• Clinical Outcome Correlation:

  • Studies have demonstrated that pY1248-ERBB2 is associated with poor clinical outcomes in breast cancer patients in both univariate and multivariate Cox regression analyses, suggesting its value as an independent prognostic marker .

• Therapeutic Response Prediction:

  • Research utilizing phospho-ERBB2 (Tyr1248) antibodies has helped identify that the phosphorylation status correlates with response to targeted therapies, potentially allowing for better patient selection for treatment .

These publications highlight the diverse applications of ERBB2 (Ab-1248) Antibody across multiple fields of biomedical research, from cancer biology to neuroscience and regenerative medicine.

What is the recommended workflow for implementing ERBB2 (Ab-1248) Antibody in a new laboratory setting?

Establishing ERBB2 (Ab-1248) Antibody in a new laboratory setting requires a systematic approach:

• Initial Planning and Setup:

  • Literature Review: Understand how others have successfully used the antibody in similar applications

  • Reagent Procurement: Purchase antibody and necessary ancillary reagents (secondary antibodies, detection systems)

  • Control Sample Acquisition: Obtain positive control samples (e.g., ERBB2-overexpressing cell lines, EGF-stimulated cells)

• Antibody Validation Phase:

  • Titration Experiments: Test a range of antibody dilutions (1:500, 1:1000, 1:2000) to determine optimal concentration

  • Protocol Optimization: Adjust blocking conditions, incubation times, and washing steps

  • Specificity Testing: Verify phospho-specificity using phosphatase treatments

  • Cross-Reactivity Assessment: Test multiple cell/tissue types to confirm expected patterns

• Application Development:

  • Method Transfer: Adapt published protocols to your laboratory's equipment and samples

  • Integration with Existing Workflows: Determine how ERBB2 phosphorylation analysis fits with other assays

  • Data Analysis Pipeline: Establish quantification methods for consistent result interpretation

• Quality Control Implementation:

  • Control Samples: Create a panel of positive and negative controls for inclusion in all experiments

  • Standard Operating Procedure (SOP) Development: Document optimized protocols in detail

  • Reference Standard Creation: Generate and store reference samples for inter-experimental comparisons

• Training and Documentation:

  • Staff Training: Ensure all laboratory members understand critical aspects of the protocol

  • Troubleshooting Guide: Create a laboratory-specific troubleshooting resource

  • Result Documentation: Establish standardized reporting formats for consistency

This structured approach will facilitate successful implementation of ERBB2 (Ab-1248) Antibody methods in a new laboratory environment while minimizing troubleshooting time and ensuring reliable results.

How can researchers ensure reproducibility when working with ERBB2 (Ab-1248) Antibody across different experimental batches?

Ensuring reproducibility with ERBB2 (Ab-1248) Antibody requires attention to several key factors:

• Reagent Management:

  • Antibody Aliquoting: Create single-use aliquots upon receipt to minimize freeze-thaw cycles

  • Lot Tracking: Document antibody lot numbers and maintain consistent lots when possible

  • Storage Conditions: Strictly adhere to recommended storage temperatures (-20°C long-term)

  • Expiration Monitoring: Track age of antibody preparations and validate older reagents

• Protocol Standardization:

  • Detailed SOPs: Create comprehensive protocols specifying all parameters (temperatures, times, volumes)

  • Equipment Calibration: Regularly calibrate critical equipment (pipettes, pH meters, imaging systems)

  • Buffer Preparation: Use consistent recipes and pH measurements for all buffers

  • Timing Consistency: Maintain consistent incubation times, particularly for primary antibody

• Sample Processing Consistency:

  • Collection Methods: Standardize sample collection procedures

  • Processing Timeline: Minimize variability in time between collection and processing

  • Phosphatase Inhibition: Use fresh phosphatase inhibitors for each experiment

  • Protein Quantification: Apply consistent protein quantification methods and loading amounts

• Internal Controls:

  • Reference Standards: Include identical positive control samples across all experiments

  • Calibration Curves: For quantitative applications, use standard curves on each experimental day

  • Technical Replicates: Include technical replicates to assess method variability

  • Normalization Strategy: Apply consistent normalization approaches (to total ERBB2 or housekeeping proteins)

• Data Management:

  • Raw Data Preservation: Maintain original unprocessed data files

  • Analysis Parameters: Document all analysis settings and algorithms

  • Batch Effect Monitoring: Plot controls over time to detect drift in assay performance

  • Metadata Tracking: Record all experimental conditions that could influence results

Implementing these practices will significantly enhance reproducibility when working with ERBB2 (Ab-1248) Antibody across different experimental batches and between researchers.